SLU-PP-332
Research Guide

Research Overview

SLU-PP-332 is a synthetic small-molecule compound studied as a pan-agonist of the estrogen-related receptors (ERRalpha, ERRbeta, and ERRgamma), a family of orphan nuclear receptors that regulate mitochondrial and oxidative-metabolism gene programs. It is an acylhydrazone (4-hydroxybenzohydrazide) derivative and is not a peptide, so it is supplied and handled as a solid small molecule rather than a lyophilized peptide. This page compiles verified identity data and summarizes the in-vitro and preclinical literature for research reference only.

In cell-based reporter assays and rodent models, SLU-PP-332 has been characterized as an exercise-mimetic tool compound: it is reported to bind the ERR ligand-binding domain and promote recruitment of the transcriptional coactivators PGC-1alpha and PGC-1beta, which are studied as master regulators of mitochondrial biogenesis. Published potency values vary by assay generation, and the compound is reported as most potent at the ERRalpha isoform.

All statements on this page describe in-vitro or preclinical (rodent) research context only. No human clinical data has been confirmed for SLU-PP-332, and nothing here should be read as a claim of human efficacy, therapeutic benefit, or fitness for any human or veterinary use. The 'High Dose' capsule strength is catalog-specific and should be confirmed against the product listing and batch COA.

Mechanism Summary

Mechanisms reported in the in-vitro and preclinical research literature include:

• SLU-PP-332 is characterized in vitro as a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta, and ERRgamma, a family of orphan nuclear receptors. In reporter assays it is reported to activate all three isoforms, with the highest reported potency at ERRalpha.
• Reported potency values differ by assay generation. The original 2023 characterization (Billon et al., ACS Chem Biol) reported an ERRalpha EC50 near 100 nM and described the compound as a pan-agonist most potent at ERRalpha. A later 2026 structure-activity study (Okda et al.) reported EC50 values of roughly 0.22 uM at ERRalpha and 0.59 uM at ERRgamma, corresponding to about 4- to 5-fold selectivity for ERRalpha over ERRgamma.
• Mechanistically, the compound is reported to bind the ERR ligand-binding domain and to promote recruitment of the transcriptional coactivators PGC-1alpha and PGC-1beta, which are studied as master regulators of mitochondrial biogenesis and the exercise-responsive transcriptional program.
• In cell models such as C2C12 myotubes and HEK293 reporter lines, SLU-PP-332 is reported to upregulate oxidative-metabolism genes (including PDK4, PGC-1alpha, and CPT1alpha) and to increase mitochondrial function and cellular respiration. On this basis it is described in the literature as an in-vitro and preclinical exercise mimetic. All of these are in-vitro or rodent-preclinical observations; no human efficacy is established.

Reference Data

Identity values are compiled from public chemistry databases and vendor documentation. Confirm the exact salt form, molecular weight, and purity for a given batch against its Certificate of Analysis (COA).

Research Applications

In laboratory research, SLU-PP-332 is studied in contexts such as:

• Studied in vitro and in mice as an ERRalpha-dependent exercise mimetic: reported to induce an acute aerobic exercise transcriptional program, increase type IIa oxidative skeletal-muscle fibers, and enhance exercise endurance in mice (Billon et al. 2023, ACS Chem Biol, PMID 36988910).
• Investigated in mouse models of diet-induced obesity and metabolic syndrome, where it is reported to increase energy expenditure and fatty-acid oxidation, decrease fat mass, and improve insulin sensitivity (Billon et al. 2024, J Pharmacol Exp Ther, PMID 37739806).
• Studied as a caloric-restriction mimetic in the aging mouse kidney: an 8-week pan-ERR-agonist course in aged mice was reported to reverse age-related mitochondrial dysfunction, albuminuria, podocyte loss, and inflammatory signaling via cGAS-STING and STAT3 pathways (Wang et al. 2023, Am J Pathol, PMID 37717940).
• Investigated as a chemical probe for ERR structure-activity relationship (SAR) work and as a scaffold for next-generation ERR agonists, including docking and molecular-dynamics modeling of ERRalpha and ERRgamma engagement (Okda et al. 2026, Int J Biol Macromol, PMID 41850449).
• Used broadly as a research tool compound to interrogate ERR-dependent transcriptional programs governing oxidative phosphorylation, TCA-cycle flux, and mitochondrial biogenesis in cell and rodent models.

Storage Information

• Because SLU-PP-332 is a solid small molecule rather than a lyophilized peptide, classic peptide reconstitution does not apply to the raw compound. Vendors report the research-grade material as a solid or powder that is soluble in organic solvents such as DMSO for in-vitro stock preparation and poorly water-soluble.
• For this finished capsule SKU, store per the catalog and batch COA. Confirm exact solvent solubility figures (mg/mL in DMSO, ethanol, or DMF) and the manufacturer-recommended storage temperature and stability window against the supplier datasheet and COA.
• For general cold-chain and stock-handling reference, see the Lyophilized Storage Guide and the Reconstitution Calculator, noting that those resources are written for peptides and that solvent choice for this small molecule should follow the supplier datasheet rather than the peptide-specific reconstitution steps.